Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005859 · ClinicalTrials.gov registry record · Phase 1
Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 136
- Enrollment target
NCT00005859 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 136 participants.
The verdict
NCT00005859, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 136 participants
- Enrollment target
Study Summary
RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of tipifarnib in treating patients who have recurrent or progressive malignant glioma.
Interventions
- DRUG tipifarnib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2000-05-16 |
| Est. Completion | 2006-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005859
The ClinicalTrials.gov registry entry for NCT00005859 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tipifarnib is the first listed.
NCT00005859 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005859 about?
NCT00005859 is a clinical study titled "Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma". RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of tipifarnib in treating patients who have recurrent or progressive malignant glioma.
What is the current status of trial NCT00005859?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 136 participants. The study started on 2000-05-16. Estimated completion is 2006-08-01.
What interventions are being tested in trial NCT00005859?
The interventions under investigation include: tipifarnib (DRUG).
Who is sponsoring clinical trial NCT00005859?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.